 The primary objective of the study is to compare the complete response CR rate of bendamustine and rituximab BR with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone R-CVP or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP in patients with advanced, indolent non-Hodgkins lymphoma NHL or mantle cell lymphoma MCL. 